Inspire Medical Systems/$INSP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Inspire Medical Systems
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
- Ticker
- $INSP
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 1,333
- Headquarters
- Golden Valley, United States
- Website
- www.inspiresleep.com
INSP Metrics
BasicAdvanced
$1.9B
19.09
$3.48
0.65
-
Price and volume
Market cap
$1.9B
Beta
0.65
52-week high
$147.03
52-week low
$38.91
Average daily volume
841K
Financial strength
Current ratio
6.448
Quick ratio
4.445
Long term debt to equity
0.035
Total debt to equity
0.035
Interest coverage (TTM)
291.25%
Profitability
EBITDA (TTM)
58.57
Gross margin (TTM)
86.19%
Net profit margin (TTM)
11.43%
Operating margin (TTM)
4.53%
Effective tax rate (TTM)
-226.78%
Revenue per employee (TTM)
$660,000
Management effectiveness
Return on assets (TTM)
2.83%
Return on equity (TTM)
13.49%
Valuation
Price to earnings (TTM)
19.092
Price to revenue (TTM)
2.179
Price to book
2.3
Price to tangible book (TTM)
2.3
Price to free cash flow (TTM)
19.609
Free cash flow yield (TTM)
5.10%
Free cash flow per share (TTM)
3.393
Growth
Revenue change (TTM)
-0.19%
Earnings per share change (TTM)
136.06%
3-year revenue growth (CAGR)
15.60%
3-year earnings per share growth (CAGR)
45.77%
What the Analysts think about INSP
Analyst ratings (Buy, Hold, Sell) for Inspire Medical Systems stock.
Analyst projections of the future price of Inspire Medical Systems stock.
Bulls say / Bears say
The AMA has approved a dedicated Category I code for single-lead hypoglossal nerve stimulation, including Inspire V, from January 2028. If reimbursement valuation is supportive, clearer billing could ease access and reduce a key barrier to adoption. (Inspire Medical Systems)
Third-quarter revenue rose 3% sequentially, and management expects low single-digit growth in 2027 as coding conditions settle. Project Horizon is intended to free about $30 million a year for growth efforts, including added support in high-potential markets. (The Motley Fool, Inspire Medical Systems)
Inspire V now makes up the vast majority of procedures, and its higher-margin sales mix helped lift gross margin. The company is also developing Inspire VI with automatic sleep detection, which could make therapy easier for patients to use. (The Motley Fool)
Coding and reimbursement problems cut about $30 million from third-quarter results, with management estimating a roughly $120 million hit for 2026. The new dedicated code does not take effect until 2028, leaving near-term billing friction in place. (Inspire Medical Systems)
Revenue fell 7.9% year on year in the third quarter, and the company expects 2026 revenue of $850–$860 million versus $912 million in 2025. Management’s low-single-digit growth outlook for 2027 points to a sharp slowdown from its earlier expansion. (Inspire Medical Systems, Investing.com)
Underlying profitability remains thin: adjusted operating income was just $1.9 million, or a 0.9% margin, in the quarter. Restructuring costs and legal expenses contributed to a $28.7 million operating loss, leaving limited room for weaker sales or higher spending. (Inspire Medical Systems)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
INSP Financial Performance
Revenues and expenses
INSP Earnings Performance
Company profitability
Upcoming events
No upcoming events
INSP News
AllArticlesVideos
Funds containing INSP
AllUSDEURGBP
Fund name | Fund size | $INSP weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.11% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.06% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.